Lyell Immunopharma, Inc. (NASDAQ:LYEL) Position Trimmed by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA trimmed its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 62.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 577,319 shares of the company's stock after selling 963,521 shares during the period. Massachusetts Financial Services Co. MA owned about 0.23% of Lyell Immunopharma worth $837,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Invenomic Capital Management LP acquired a new position in Lyell Immunopharma during the fourth quarter valued at approximately $1,448,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Lyell Immunopharma during the first quarter valued at approximately $191,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Lyell Immunopharma during the fourth quarter valued at approximately $31,000. Acadian Asset Management LLC purchased a new stake in shares of Lyell Immunopharma during the first quarter valued at approximately $173,000. Finally, TD Asset Management Inc raised its stake in shares of Lyell Immunopharma by 4.2% during the second quarter. TD Asset Management Inc now owns 1,004,642 shares of the company's stock valued at $1,457,000 after purchasing an additional 40,800 shares during the period. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL traded down $0.08 during midday trading on Monday, reaching $1.43. The company had a trading volume of 1,357,947 shares, compared to its average volume of 924,586. The stock's fifty day moving average price is $1.45 and its 200-day moving average price is $1.97. The stock has a market capitalization of $364.56 million, a P/E ratio of -1.63 and a beta of -0.53. Lyell Immunopharma, Inc. has a one year low of $1.09 and a one year high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 389,368.50% and a negative return on equity of 33.35%. As a group, sell-side analysts forecast that Lyell Immunopharma, Inc. will post -0.85 earnings per share for the current year.

Wall Street Analyst Weigh In

LYEL has been the topic of a number of analyst reports. HC Wainwright reiterated a "neutral" rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research note on Monday, August 19th. Bank of America dropped their price objective on shares of Lyell Immunopharma from $9.00 to $6.00 and set a "buy" rating on the stock in a research note on Thursday, June 27th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.